Patents Assigned to Life Sciences Research Partners
  • Antibodies which bind and inhibit blood factor VIII
    Patent number: 8293234
    Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: October 23, 2012
    Assignee: Life Sciences Research Partners
    Inventors: Jean-Marie Saint-Remy, Marc Jacquemin
  • Antibodies which bind and inhibit blood factor VIII
    Patent number: 8282923
    Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: October 9, 2012
    Assignee: Life Sciences Research Partners
    Inventors: Jean-Marie Saint-Remy, Marc Jacquemin
  • Methods for treating or inhibiting thromboembolic disorders or for inhibiting coagulation
    Patent number: 8277805
    Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: October 2, 2012
    Assignee: Life Sciences Research Partners
    Inventors: Jean-Marie Saint-Remy, Marc Jacquemin